Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference [Yahoo! Finance]
Cadrenal Therapeutics, Inc. (CVKD)
Company Research
Source: Yahoo! Finance
late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced its participation at the upcoming Technology and Heart Failure Therapeutics Conference (THT 2024), which is produced by the Cardiovascular Research Foundation (CRF), taking place March 4-6, 2024 in Boston THT 2024 offers a unique perspective by uniting device- and technology-based therapies with drug-based approaches, effectively bridging gaps in current practices. Attendees can expect comprehensive updates on the status of treatments for heart failure, spanning drug and device solutions, left ventricular ejection fractions, and the latest pivotal studies yet to be published or included in guidelines. Quang Pham , Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics, commented, "Patients with cardiac implanted medical devices such as mechanical heart valves (MH
Show less
Read more
Impact Snapshot
Event Time:
CVKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVKD alerts
High impacting Cadrenal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CVKD
News
- Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update [Yahoo! Finance]Yahoo! Finance
- Cadrenal Therapeutics Provides First Quarter 2024 Corporate UpdatePR Newswire
- Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]Yahoo! Finance
- Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 [Yahoo! Finance]Yahoo! Finance
CVKD
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/10/24 - Form 4
- CVKD's page on the SEC website